Steve Uden, co-founder and CEO of RallyBio, shares his insights about leadership in biopharma and how Rallybio is working to to profoundly  change the odds for patients living with rare diseases.

Karine Rossignol, co-founder and CEO of Smart Immune, shares her insights with BioBoss host John Simboli about leadership in biopharma and how Smart Immune is working to harness a patient's own thymus to re-arm the immune system against cancer and infection.

Lisa Deschamps, CEO of AviadoBio, shares her thoughts with BioBoss host John Simboli about leadership in biopharma and how AviadoBio is working to develop transformative medicines for patients living with debilitating and life-threatening neurodegenerative disorders.

Leonard Mazur, founder and CEO of Citius Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Citius is working to unlock the potential of first-in-class critical care therapeutics, with a pipeline of anti-infectives in oncology, adjunct cancer care and stem cell therapy.

Dario Neri, co-founder and CEO of Philogen, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Philogen is working to discover and develop targeted therapies to treat cancer and chronic inflammation.

Naseem Amin,  CEO of Orphalan, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Orphalan is working to transform rare disease treatment.

Hartmut Ehrlich,  CEO of Abivax, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Abivax is working to develop treatments modulating the body’s natural immune system to treat patients with chronic inflammatory diseases, viral infections and cancer.

Ivo Timmermans, co-founder and  CEO of Pleco Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Pleco is working to develop breakthrough therapies that change the balance in the treatment of cancer.

Philipp Spycher, co-founder and  CEO of Araris Biotech, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Araris is working to develop a linker technology for antibody-drug conjugates that enables attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

Pat Arensdorf, founder and  CEO of Exai Bio, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Exai is working to develop a next-generation RNA-based platform to deliver actionable insight into cancer biology from a simple blood draw.

Josh Geballe, Managing Director of Yale Ventures, shares his thoughts with BioBoss host John Simboli about leadership and community building in biopharma. Yale Ventures is a new initiative created by Yale University to support and expand innovation and entrepreneurship across Yale university and throughout the greater New Haven region with the goal of helping to develop innovations that impact the world's greatest challenges.

BioBoss podcast host John Simboli reflects on the success of seasons 1, 2 ,3 and 4 and welcomes listeners to listen in on his conversations about leadership with biopharma founders and CEOs in  BioBoss season 5.

John is delighted to open BioBoss season 5 with his conversation with Josh Geballe, Managing Director of Yale Ventures, who shares his thoughts about leadership, innovation, entrepreneurship and community building in biopharma and biotech. Yale Ventures is a new initiative created by Yale University to support and expand innovation and entrepreneurship across Yale university and throughout the greater New Haven region with the goal of helping to develop innovations that impact the world's greatest challenges.

Erik Buntinx, founder and CEO of ANeuroTech, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how ANeurotech is working to develop effective treatments, with minimal or no side-effects, for patients who suffer with depression

Luca Benatti,  CEO of EryDel, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how EryDel is working to develop specialized therapies for the treatment of rare diseases by using the patient’s own blood.

Elisabet de los Pinos, founder and CEO of Aura Biosciences, shares her thoughts with BioBoss host John Simboli about leadership in biopharma and how Aura is working to envision new ways to treat cancer.

Paul Radspinner, founder and CEO of Flugen, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Flugen is working to develop a more effective vaccine in the fight against influenza and respiratory disease.

Jesús Martin-Garcia, CEO of GeNeuro, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Geneuro is working to develop treatments against neurological disorders and autoimmune diseases by neutralizing causal factors encoded by Human Endogenous Retroviruses.

Cliff Stocks, founder and CEO of OncoResponse speaks with BioBoss host John Simboli. Hear Cliff’s insights about leadership in biopharma and how OncoResponse is working to identify fully human monoclonal antibodies as therapeutics for the treatment of cancer.

Brian Finrow, Co-founder and CEO of Lumen Bioscience, speaks with BioBoss host and biopharma branding veteran John Simboli. Hear Brian’s thoughts about leadership and how Lumen Biosciences is working to unlock the full potential of biologic drugs, whose promise has been held back by the lack of scalable technology. 

BioBoss host John Simboli speaks with Alex Blyth,  founder and CEO of LifT BioSciences.

Hear Andrew speak with BioBoss host John Simboli about leadership in biopharma and how IMV is working on advancing a portfolio of therapies based on the Company’s immune-educating platform.

Kevin Lee, CEO of Bicycle Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Bicycle Therapeutics is working on developing a new class of medicines, called Bicycles, for diseases that are underserved by existing therapeutics. 

BioBoss host John Simboli speaks with Reenie McCarthy, CEO of Stealth BioTherapeutics, headquartered in Needham, MA.. Hear Reenie's thoughts about leadership in biopharma and how Stealth Biotherapeutics is working on developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases.

Helen Torley, CEO of Halozyme Therapeutics, shares her thoughts with BioBoss host John Simboli about leadership in biopharma and how Halozyme is working to reinvent the patient experience by easing the burden of treatment and improving patient outcomes.

BioBoss host John Simboli speaks with Yochi Slonim, founder and CEO of Anima Biotech, headquartered in Boston with R&D in Tel Aviv.. Hear Yochi's thoughts about leadership in biopharma and how Anima Biotech is working on a novel approach for the discovery of small molecules that selectively control mRNA translation as a new strategy against undruggable proteins.

BioBoss host John Simboli speaks with Clive Richardson, CEO of Akari Therapeutics, headquartered in London with offices in New York. Hear Clive's thoughts about leadership in biopharma and how Akari Therapeutics  is working to develop life-transforming treatments for autoinflammatory diseases involving the complement and leukotriene  pathways

BioBoss podcast host John Simboli reflects on the success of seasons 1, 2 and 3 and welcomes listeners to listen in on his conversations about leadership with biopharma founders and CEOs in  BioBoss season 4.

BioBoss host John Simboli speaks with Stefan König , CEO of George Medicines, headquartered in London. Hear Stefan’s thoughts about leadership in biopharma and how George Medicines is working to extend and improve the lives of people suffering from the world’s leading causes of death and disability—including hypertension, cardiovascular disease and type 2 diabetes

Derek Maetzold, CEO of Castle Biosciences shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Castle is leveraging its expertise in cancer genomics and the use of artificial intelligence to improve patient outcomes.

Bob Cobuzzi, Chief Executive Officer of Diffusion Pharmaceuticals,speaks with BioBoss John Simboli about leadership and how Diffusion Pharmaceuticals is working to develop novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most.

Panna Sharma, CEO of Lantern Pharma, headquartered in Dallas, Texas, shares his thoughts with BioBoss host John Simboli about leadership and how Lantern is working at the intersection of artificial intelligence, genomics and machine learning to advance precision oncology therapies.

Nandan Padukone, CEO of IM Therapeutics, headquartered in Woburn, Massachusetts, shares his thoughts with BioBoss host John Simboli about leadership and how IM Therapeutics is targeting the root cause of autoimmunity with therapeutic design directed at human leukocyte antigens.

"I think I've always found motivation from being able to take a highly technical topic and dig in. I'm never the person that knows most about the topic. But I strive to be like the person who knows third or fourth most about whatever topic is going." 

– Mathew Gline: CEO of Roivant Sciences

Koen De Witte, managing director of reMYND NV, headquartered in Leuven, Belgium, shares his thoughts with BioBoss host John Simboli about leadership and how reMYND is advancing treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction. 

James Graham, CEO of Recce Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Recce is working to develop a new class of synthetic anti-infectives designed to address the threat of antibiotic-resistant superbugs.

Lanny Sun, co-founder of Silicon Therapeutics, recently acquired by Roivant Sciences. speaks with corporate branding veteran John Simboli about leadership in biopharma. Lanny also discusses how Silicon Therapeutics, now part of Roivant Drug Discovery, is advancing its chip-to-clinic, computational quantum physics-based approach to pioneer a new path for drug design of  medicines to improve the lives of patients

Joan Perelló, co-founder and CEO of Sanifit, shares his thoughts with BioBoss host John Simboli about leadership and how Sanifit is pursuing the development of treatments for progressive vascular calcification disorders.

Saiid Zarrabian, President and CEO of Kintara Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership and how Kintara is pursuing the development of new cancer therapies for patients with rare unmet medical needs.

John Temperato, President and Chief Executive Officer of 9 Meters Biopharma, speaks with BioBoss host John Simboli about leadership in biopharma and how 9 Meters is advancing drug candidates for patients with rare and unmet gastrointestinal disorders including short bowel syndrome and celiac disease. 

Shawn Singh, CEO of VistaGen, speaks with BioBoss host John Simboli about leadership and VistaGen's working to develop a new generation of medications for anxiety, depression and other central nervous system disorders.

BioBoss podcast host John Simboli reflects on the success of seasons 1 and 2 and welcomes listeners to listen in on his conversations about leadership with biopharma founders and CEOs in  BioBoss season 3.

Bobby Gaspar, founder and  CEO of Orchard Therapeutics, speaks with BioBoss host John Simboli about leadership and how Orchard Therapeutics is pursuing the opportunity to change medicine and change the lives of people with severe genetic diseases. 

Itamar Kandel, CEO of HeartVista, speaks with BioBoss host John Simboli about leadership and how HeartVista leverages machine learning to simplify diagnostic imaging and help physicians more accurately diagnose cardiovascular disease.

Mark Altmeyer, founder and CEO of Arvelle Therapeutics, speaks with BioBoss host John Simboli. Hear Mark’s thoughts about leadership and how Arvelle is working to bring new solutions to people living with epilepsy and CNS disorders.

Jacob Becraft, co-founder & CEO of Strand Therapeutics shares his thoughts with BioBoss host John Simboli about leadership and how Strand is working in synthetic biology and messenger RNA to target root causes of genetic disease, with the power to control editing at a single-cell level.

Mike Gaffney, CEO of Cellphire Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Cellphire is working to save lives by bringing novel hemostatic products to patients in need.

Eran Eden, co-founder and CEO of MeMed, shares his thoughts on leadership and how MeMed is working to translate signals from the immune system into diagnostic insights to treat infectious disease and inflammatory disorders. 

Nikolaj Sørensen, CEO of Orexo Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership and, digital and bio-therapeutics, how the coronavirus is changing the landscape around mental health, depression, substance abuse and addiction,

Per Hellsund, co-founder and CEO of Cybrexa Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership, building a culture of transparency, and Cybrexa's advances in treating the cancer tumor microenvironment.

CEO Clive Morris of Inivata, headquartered in Cambridge U.K., shares his thoughts with BioBoss host John Simboli about leadership in biotech and advances in non-invasive liquid biopsy to unlock genomic information and guide personalized cancer treatment.